CureVac/CVAC

$2.44

0%
-
1D1W1MYTD1YMAX

About CureVac

CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people’s lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.

Ticker

CVAC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Alexander Zehnder

Employees

1,049

Headquarters

Tuebingen, Germany

CureVac Metrics

BasicAdvanced
$575.48M
Market cap
-
P/E ratio
-$1.48
EPS
2.50
Beta
-
Dividend rate
$575.48M
2.49569
$12.36
$2.54
775.93K
3.563
3.408
6.074
6.993
-34.49%
-49.26%
-42.28%
12.577
0.895
0.943
-55.77%
-113.42%
57.02%

What the Analysts think about CureVac

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 6 analysts.
441.8% upside
High $20.86
Low $2.98
$2.44
Current price
$13.22
Average price target

CureVac Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-296.34% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
€16.4M
118.67%
Net income
€-48.6M
-27.89%
Profit margin
-296.34%
-67.02%

CureVac Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 3.51%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-€0.60
-€0.27
-€0.30
-€0.22
-
Expected
-€0.31
-€0.34
-€0.24
-€0.23
-€0.19
Surprise
95.12%
-20.59%
25%
-3.51%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for CureVac stock?

CureVac (CVAC) has a market cap of $546.37M as of April 21, 2024.

What is the P/E ratio for CureVac stock?

The price to earnings (P/E) ratio for CureVac (CVAC) stock is 0 as of April 21, 2024.

Does CureVac stock pay dividends?

No, CureVac (CVAC) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next CureVac dividend payment date?

CureVac (CVAC) stock does not pay dividends to its shareholders.

What is the beta indicator for CureVac?

CureVac (CVAC) has a beta rating of 2.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the CureVac stock price target?

The target price for CureVac (CVAC) stock is $13.28, which is 444.26% above the current price of $2.44. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell CureVac stock

Buy or sell CureVac stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing